Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Change in Acquisitions & Divestments (2016 - 2021)

Historic Change in Acquisitions & Divestments for Akebia Therapeutics (AKBA) over the last 6 years, with Q2 2021 value amounting to $20.0 million.

  • Akebia Therapeutics' Change in Acquisitions & Divestments changed N/A to $20.0 million in Q2 2021 from the same period last year, while for Mar 2022 it was $20.0 million, marking a year-over-year decrease of 7500.0%. This contributed to the annual value of $40.0 million for FY2021, which is 3360.44% down from last year.
  • As of Q2 2021, Akebia Therapeutics' Change in Acquisitions & Divestments stood at $20.0 million.
  • Akebia Therapeutics' Change in Acquisitions & Divestments' 5-year high stood at $78.7 million during Q1 2019, with a 5-year trough of $245000.0 in Q1 2020.
  • In the last 5 years, Akebia Therapeutics' Change in Acquisitions & Divestments had a median value of $36.7 million in 2017 and averaged $40.4 million.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first crashed by 9968.87% in 2020, then soared by 806326.53% in 2021.
  • Akebia Therapeutics' Change in Acquisitions & Divestments (Quarter) stood at $52.1 million in 2017, then grew by 21.19% to $63.2 million in 2018, then crashed by 64.39% to $22.5 million in 2019, then surged by 166.67% to $60.0 million in 2020, then tumbled by 66.67% to $20.0 million in 2021.
  • Its last three reported values are $20.0 million in Q2 2021, $20.0 million for Q1 2021, and $60.0 million during Q4 2020.